Canopy Growth Corporation (CGC)

Several events have impacted Canopy Growth's stock price in the past six months. Canopy Growth announced a definitive agreement to acquire MTL Cannabis Corp. in December 2025, which was completed in March 2026. Reports in December 2025 suggested the U.S. administration was considering reclassifying cannabis as a Schedule III drug. In early 2026, the company recapitalized its balance sheet. Canopy Growth has faced ongoing litigation, including a class action lawsuit filed in April 2025 and a Canadian court certified class action in January 2026. The company released its Q2 and Q3 Fiscal 2026 financial results in November 2025 and February 2026, respectively. In January 2026, Canopy Growth announced the appointment of David Männer as Managing Director of Storz & Bickel. The stock has been described as a "penny stock" trading around $1.

Demand seasonality in the cannabis industry shows consistent trends. Significant peaks in cannabis sales occur around April 20th (4/20) and during the holiday season. Flower category tends to be relatively stable year-round, while pre-rolls, vapes, edibles, and beverages exhibit more meaningful demand movement throughout the year. Spring sales build across April, driven by 4/20, and summer months show strength in portable and social formats. November and December generate a second wave for edibles and vapes, influenced by holiday gifting and indoor consumption.

Canopy Growth Corporation is a Canadian cannabis company involved in the production, distribution, and sale of cannabis, hemp, and related products for medical and recreational markets. The company operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry, also identified as the Cannabis industry. Canopy Growth offers a diverse portfolio of products, including dried flower, pre-rolls, extracts, concentrates, beverages, vapes, and edibles, sold under various brands. The company's Spectrum Therapeutics medical platform provides oils, softgels, and flower products.

Canopy Growth's principal operations are in Canada, Europe, and Australia, participating in both the medical and adult-use markets in Canada. Its international footprint also includes operations in Germany and the United States through Canopy USA, LLC. Historically, Canopy Growth has had partnerships or operations in Spain, the Czech Republic, Lesotho, Jamaica, Chile, Peru, and Brazil. The company has previously ceased farming operations in the United States and cultivation in Colombia, moving to an asset-light model in the latter.

Canopy Growth aims to "unleash the power of cannabis to improve lives" and operates a global cannabis platform. Ongoing litigation and financial struggles may negatively affect public perception and investor trust. In March 2026, Canopy Growth's Apollo Cannabis Clinics were named the Best Medical Cannabis Clinic.

Canopy Growth Corporation's ownership is a mix of institutional, retail, and individual investors. Key institutional shareholders include Jane Street Group, Llc, Toroso Investments, LLC, Susquehanna International Group, Llp, D. E. Shaw & Co., Inc., Leonteq Securities AG, Citadel Advisors Llc, Morgan Stanley, and Caitong International Asset Management Co. Ltd. Greenstar II Holdings LLC is noted as the largest individual Canopy Growth shareholder.